“We have provided an updated cash runway guidance into 2029, and this past quarter we made significant progress on the darovasertib program, including receiving U.S. FDA breakthrough therapy designation, and enrollment is ahead of schedule with over 300 patients in the 1L HLA-A2-negative MUM registrational trial for a targeted median PFS readout by year-end to enable a potential accelerated approval filing next year. We also advanced a broad clinical pipeline of potential first-in-class programs to continue to drive forward our growth strategy, including DLL3 TOP1 ADC IDE849 in lung cancer, Werner Helicase inhibitor IDE275 in MSI-high colorectal and endometrial cancer, and MAT2A inhibitor IDE397 in MTAP-deletion lung and urothelial cancer,” said Yujiro Hata, president and CEO, Ideaya Biosciences (IDYA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences’ Trial Expansion and Regulatory Uncertainties Lead to Hold Rating
- IDEAYA Biosciences: Promising Prospects with Strategic Phase 3 Trial and Key Data Catalysts
- IDEAYA Biosciences: Promising Outlook with Regulatory Alignment and Strategic Expansion in Clinical Trials
- Ideaya trial design consisent with guidance, says Oppenheimer
- Morning Movers: Goldman Sachs gains following first quarter results